02.2Healthcare & Medical
Pharma & biotech
In pharma and biotech the science is only half the risk; the other half is capital strategy, portfolio choices, and a commercial launch that has to land in a narrow window. The bets are long, expensive, and unforgiving.
The terrain
What actually decides outcomes here.
Drug development is a long-odds, capital-intensive business where a single portfolio or launch decision can define a company. The timelines dwarf almost every other industry, the regulatory and evidence requirements are absolute, and the commercial value is concentrated into launch and lifecycle windows that reward preparation and punish improvisation.
We work above the science, on the business decisions that surround it — portfolio and capital strategy, commercial and launch planning, and the operating model that turns a pipeline into a business. Our founder's background is in M&A, valuation, and capital strategy, which is squarely the analytical rigor this sector's biggest decisions demand.
- Practice
- Healthcare & Medical
- Taxonomy
- 02.2
- Reach
- Worldwide
The hard calls
Where the decisions get expensive.
- 01
Portfolio and capital allocation
With finite capital and long timelines, which programs to fund and which to cut is the defining decision. We bring valuation and scenario rigor to the portfolio calls that shape the company.
- 02
Commercial launch in a narrow window
Value concentrates into a launch that has to execute. We help build the commercial and launch strategy — access, positioning, and readiness — before the window opens, not during it.
- 03
Business development and deal strategy
Licensing, partnerships, and M&A are how pipelines get built and de-risked. We bring transaction-grade analysis to what to buy, partner, or license, and on what terms.
- 04
AI in discovery — signal versus story
AI-driven discovery is real in places and overstated in others. We help separate where it genuinely changes the economics from where it's a narrative, and invest accordingly.
Where we start
The services that fit this sector.
- View service
Financial advisory (executive level)
Portfolio, capital-allocation, and M&A decisions that carry transaction-grade stakes.
- View service
Strategy consulting
Commercial, access, and launch strategy in a value-concentrated window.
- View service
Innovation consulting
Build and validate new therapeutic or commercial models before betting the capital.
- View service
Compliance consulting
Frameworks for a sector where regulatory rigor is absolute and non-negotiable.
Questions
Before you reach out.
- Do you have clinical or regulatory affairs expertise?
- No — those belong to your clinical and regulatory teams. We work on the commercial, portfolio, capital, and deal strategy around the science, where the analytical rigor of our background is the fit.
- Can you help evaluate a licensing or M&A opportunity?
- Yes. Transaction analysis — valuation, structure, and the strategic case — is core strength. We bring the same rigor to a licensing deal or acquisition that the decision's stakes demand, alongside your scientific due diligence.
Bring us a pharma & biotech decision.
A first conversation is a scoping conversation — no obligation, no packaged pitch. Tell us what you're deciding, and we'll tell you honestly whether we're the right firm for it.
No obligation · a scoping conversation first